94 results about "Foam cell" patented technology

New methods of ultrasound imaging are presented that provide images with reduced reverberation noise and images of nonlinear scattering and propagation parameters of the object, and estimation of corrections for wave front aberrations produced by spatial variations in the ultrasound propagation velocity. The methods are based on processing of the received signal from transmitted dual frequency band ultrasound pulse complexes with overlapping high and low frequency pulses. The high frequency pulse is used for the image reconstruction and the low frequency pulse is used to manipulate the nonlinear scattering and / or propagation properties of the high frequency pulse. A 1st method uses the scattered signal from a single dual band pulse complex for filtering in the fast time (depth time) to provide a signal with suppression of reverberation noise and with 1st harmonic sensitivity and increased spatial resolution. In other methods two or more dual band pulse complexes are transmitted where the frequency and / or the phase and / or the amplitude of the low frequency pulse vary for each transmitted pulse complex. Through filtering in the pulse number coordinate and corrections of nonlinear propagation delays and optionally also amplitudes, a linear back scattering signal with suppressed pulse reverberation noise, a nonlinear back scattering signal, and quantitative nonlinear scattering and forward propagation parameters are extracted. The reverberation suppressed signals are further useful for estimation of corrections of wave front aberrations, and especially useful with broad transmit beams for multiple parallel receive beams. Approximate estimates of aberration corrections are given. The nonlinear signal is useful for imaging of differences in tissue properties, such as micro-calcifications, in-growth of fibrous tissue or foam cells, or micro gas bubbles as found with decompression or injected as ultrasound contrast agent.

A wound treatment-dressing is shown which includes a dressing body formed from a medically inert, moisture permeable, urethane open-cell foam which is hydrophilic in nature. The foam body has a foam matrix of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobials as active agents, the active agents being incorporated into the foam matrix both topically on a foam cell surface and integrally within the foam cell wall. The antimicrobials are manufactured in a selected particle size range which improves predictability and performance of the wound dressing.

The present invention discloses an article made from a foamable thermoplastic polymer composition. The foamable composition of the article includes a partially-crystalline melt processible perfluoropolymer and a foam nucleating package. The foamable composition of the article has a uniform foam cell size where the foam cell size of at least 90% of the foamed cells is 50 micrometers or less. The foam nucleating package ranges from 0.1 to 10 wt % of the combined weight of the perfluoropolymer and the foam nucleating package.

Apparatus for protecting a user from impacts to the head. The apparatus includes a shell configured to receive a human head and a plurality of structures attached to the outer surface of the shell, where each structure is independently coupled to the shell with a respective assembly. The structures move independently of one another but are restricted to moving laterally along the outer surface of the shell. The structures each include a foam cell that reduces the magnitude of a head-on impact as the impact transfers from the foam cell to the shell. The assemblies each include an elastomeric donut that reduces the magnitude of a lateral impact as the impact is transferred from the foam cell to the donut assembly to the shell. Thus, a user is protected from the concussive effects of a head-on impact and the rotational acceleration injuries of a lateral impact.

The present invention provides a compound of the formula (I):wherein R1, R2, R3 and R4 are each independently hydrogen, optionally substituted alkyl, hydroxy, optionally substituted alkoxy or the like, R5 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocyclic or the like, R6 is hydrogen, optionally substituted alkyl or the like, R7 is hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclic or the like, A is S or O and a broken line represents presence or absence of a bond,pharmaceutically acceptable salt or hydrate thereof and a pharmaceutical composition or a pharmaceutical composition for use as an endothelin receptor antagonist, a peripheral circulation insufficiency-improving agent or a macrophage foam cell formation inhibitor comprising the compound.

Cell nucleation compositions and pellets, methods for making same, methods and compositions for making polymer foam, and polymer foams made by the methods are disclosed.

The present invention relates to a hydrophilic foam material, which is of particular use in wound treatment, and to a method for producing said hydrophilic foam material. The hydrophilic foam material has nucleating particles, wherein at least 85% of all foam cells in said foam material have an average cell size of 0.01 mm2 or less.

Apparatus for protecting a user from impacts to the head. The apparatus includes a shell configured to receive a human head and a plurality of structures attached to the outer surface of the shell, where each structure is independently coupled to the shell with a respective assembly. The structures move independently of one another but are restricted to moving laterally along the outer surface of the shell. The structures each include a foam cell that reduces the magnitude of a head-on impact as the impact transfers from the foam cell to the shell. The assemblies each include an elastomeric donut that reduces the magnitude of a lateral impact as the impact is transferred from the foam cell to the donut assembly to the shell. Thus, a user is protected from the concussive effects of a head-on impact and the rotational acceleration injuries of a lateral impact.

The present invention relates to the use of a composition comprising a combination of diacylglycerol(s) (DAG), mainly 1,3-diacylglycerol(s), and phytosterol and / or phytostanol ester(s) (PSE) dissolved or dispersed in edible oil and / or edible fat, in the manufacture of nutritional supplements and orally administrable pharmaceutical preparations which are capable of reducing blood levels of both cholesterol and triglycerides and / or for lowering serum, serum LDL and macrophage oxidation levels, inhibiting the formation of foam cells and / or preventing the deleterious effects generated by lipid-induced oxidative stress. In addition, the composition of the invention, as well as the pharmaceutical preparations thereof, is suitable for the treatment and prevention of conditions related to atherosclerosis, such as cardiovascular disease (CVD), coronary heart disease (CHD) and diabetes mellitus.

A wound treatment-dressing is shown which includes a dressing body formed from a medically inert, moisture permeable, urethane open-cell foam which is hydrophilic in nature. The foam body has a foam matrix of interconnected foam cells with cell walls which have incorporated therein a combination of inorganic antimicrobials as active agents, the active agents being incorporated into the foam matrix both topically on a foam cell surface and integrally within the foam cell wall. The antimicrobials are manufactured in a selected particle size range which improves predictability and performance of the wound dressing.

The invention provides a medical polyurethane foam dressing. The medical polyurethane foam dressing is prepared from the following components in percentage by mass: 55 to 70 percent of waterborne polyurethane prepolymer, 2 to 3.5 percent of a catalyst, 6 to 10 percent of a surfactant, 0.5 to 5 percent of a crosslinking agent, 2 to 10 percent of sodium alginate, 2 to 10 percent of sodium carboxymethylcellulose, 0.3 to 2.5 percent of an anti-yellowing agent and the balance of purified water. The formula raw materials of the medical polyurethane foam dressing, disclosed by the invention, does notcontain organotin, the toxicity of the catalyst is lower, the content of the organotin does not need to be detected when quality control is performed and the environmental protection performance is better; in addition, the Yi value is determined by using a spectrophotometer, and the difference value of Yi measured before and after irradiation is smaller than 1.5, which shows that almost no yellowing behavior is caused. The preparation method has the advantages of simplicity and no stimulation to skin; besides, the foam cytotoxicity is detected to be a first level by referring to GBT 16886.5 and the requirements are met.

The invention discloses a molecular marker for diagnosing atherosclerosis and an application of the marker, belongs to the technical field of biological engineering and relates to an application of areagent for detecting the expression level of SCRAB1 in blood vessel samples to preparation of products for diagnosing the atherosclerosis, and A sequence of the SCRAB1 is as shown in SEQ: ID: NO: 1.ApoE knockout mice and THP-1 source foam cells serve as research objects, RNA (ribonucleic acid) of tissues or cells is extracted, expression change of the gene SCRAB1 related to AS lipid is observed,cellular level validation is implemented, and a deposition specificity diagnosis method of the AS lipid comprising the SCRAB1 is built. The method is simple and reliable, materials are conveniently taken, sensitivity and specificity of the method are highly consistent with those of imaging diagnosis and gross specimen staining, and the method has high application values in early diagnosis and prognosis evaluation of AS diseases.

The invention discloses a method for screening atherosclerosis related miRNA, which comprises the following steps: selecting ox-LDL (30mu g / ml) as a stimulating factor to stimulate human primary monocyte and induce the human primary monocyte to be differentiated into macrophage and foam cell, detecting the difference of cellular miRNAs expression in vitro by combining microarray analysis technology, screening the miRNAs which possibly participate in atherosclerosis reaction, and then using tagman probe fluorescent quantitative PCR verification and using a database and a computer software to analyze and forecast a possible target mRNA corresponding to the screened miRNAs; therefore, the method furthest screens the miRNA close to an atherosclerosis specific inflammation reaction pathological state, further completes a forming mechanism of atherosclerosis, and develops a new treatment target and a method for preventing and treating the atherosclerosis, in particular acute coronary events.

The invention discloses a red mud compound type foaming agent. The technical scheme is characterized in that the red mud compound type foaming agent comprises red mud powder, attapulgite clay powder having an air purification function, hydrogen peroxide, N,N-dimethyldodecylamine-N-oxide, coconut diethanolamide, modified polyethoxylated silicone, polyether modified silicone oil and water; paste ingredients of the red mud compound type foaming agent are firstly stirred into a paste, and then ingredients of the red mud compound type foaming agent are stirred and form a finished product of the red mud compound type foaming agent. The red mud compound type foaming agent has the characteristics of high foaming capability, high foam expansion rate, large foaming quantity per unit volume, uniform and fine foam cells, low possibility of breakage of foam cells, high demolding speed of a product, good surface smoothness and high long-term strength of the product. The product produced with the red mud compound type foaming agent has heat-preservation, thermal-insulation and soundproof effects and has an air purification function; and the red mud compound type foaming agent is suitable for producing light boards, light walls and noise reduction products.

The invention discloses a bentonite compound type foaming agent. The technical scheme is characterized in that the bentonite compound type foaming agent comprises activated clay, attapulgite clay powder having an air purification function, hydrogen peroxide, N,N-dimethyldodecylamine-N-oxide, coconut diethanolamide, a silicone resin polyether emulsion, polyether modified silicone oil and water; and paste ingredients of the bentonite compound type foaming agent are firstly stirred into paste, and then ingredients of the bentonite compound type foaming agent are stirred and form a finished product of the bentonite compound type foaming agent. The bentonite compound type foaming agent has the characteristics of large foaming quantity per unit volume, uniform and fine foam cells, low possibility of breaking of foam cells, high demolding speed of the product, good surface smoothness and high later strength of the product. The product produced with the bentonite compound type foaming agent has heat-preservation, thermal-insulation and soundproof effects and has an air purification function; and the bentonite compound type foaming agent is suitable for producing a light board, a light wall and a noise reduction product.

The invention relates to a Yunnan olive freeze-dried ultrafine powder buccal tablet, a preparation method and application thereof, and belongs to the field of traditional Chinese medicine preparation.The freeze-dried ultrafine powder buccal tablets of Yunnan olive obtained by ultrafine pulverization technology have good dispersibility and solubility, which is favorable for drug release and absorption, can improve bioavailability, is favorable for molding, and is widely used. The freeze-dried ultrafine powder buccal tablets of Yunnan olive can reduce the transformation of macrophages into lipid-rich foam cells.

The invention discloses a pleurotus eryngii polysaccharide capable of reducing the accumulation of foam cell lipid and a preparation method of the pleurotus eryngii polysaccharide. The pleurotus eryngii polysaccharide is the pleurotus eryngii polysaccharide PEPE-1 of which the average molecular weight is 37.50kDa or the pleurotus eryngii polysaccharide PEPE-2 of which the average molecular weight is 30.00kDa; and the monosaccharide mainly consists of glucose, and a small quantity of mannose and galactose. The preparation method of the pleurotus eryngii polysaccharide comprises the following steps of: digesting and dialyzing pleurotus eryngii sporocarp dry powder by hot water, and further passing through an anion-exchange column DEAE-52 and separating and purifying by the salt concentration gradient elution to obtain PEPE-A; and further separating and purifying the PEPE-A by SephadexG-100, so that the components PEPE-1 and PEPE-2 can be obtained. The PEPE-1 and the PEPE-2 have a single peak, so that the pleurotus eryngii polysaccharide can preferably prevent the foam cell lipid accumulation function and the anti-oxygenation function; and the pleurotus eryngii polysaccharide can be used as a food additive.

An electroconductive roller including an electroconductive cellular material layer, comprised of a polyurethane composition, which has an average foamed cell diameter not more than 100 μm and a variation ΔD of the foamed cell diameter not more than 50 μm. The electroconductive roller has a hardness variation ΔHs not more than 8 degrees and a circumferential non-uniformity index RMAX / RMIN in an electric resistance thereof not more than 1.3. The electroconductive cellular material layer is made of a thermosetting one-part polyurethane composition. And the polyurethane composition is cured instantly at a temperature not less than a thermosetting critical temperature for curing thereof, after it is foamed by a mechanical foaming method.

The invention discloses a compound type basalt foaming agent. The technical scheme of the foaming agent is characterized in that the compound type basalt foaming agent comprises vesicular basalt powder, attapulgite china clay powder having an air purification function, hydrogen peroxide, dodecyl dimethyl amine oxide, coconut diethanolamide, modified polyethoxylated silicone, modified polyether silicone and water. Compound type basalt foaming agent paste ingredients are stirred into a paste, and then the ingredients are stirred into a finished product of the compound type basalt foaming agent. The compound type basalt foaming agent has the characteristics as follows: the foaming capacity and the foam expansion are high, foam producing amount in unit volume is large, foam cells are fine, smooth and not prone to be broken, a demolding speed of a product is high, the surface smoothness is good, and the later strength of the product is high; the product produced with the compound type basalt foaming agent not only has the effects of heat preservation, thermal insulation and sound insulation, but also has the air purification function; and the compound type basalt foaming agent is suitable for producing lightweight boards, lightweight walls and noise reduction products.

The invention relates to a method for improving the cell retraction behavior of a thermoplastic elastomer microcellular foam material, and belongs to the field of thermoplastic elastomer microcellularfoaming. The method for inhibiting the cell retraction of the thermoplastic elastomer microcellular foam material is characterized in that nanoparticles are introduced in the process of preparing thethermoplastic elastomer microcellular foam material, and the nanoparticles and the thermoplastic elastomer have a physical bonding or chemical crosslinking effect, thereby inhibiting cell retractionafter foaming of the foam material. The invention aims to provide the method for conveniently and efficiently improving the cell retraction behavior of the thermoplastic elastomer from the perspectiveof a molecular chain, and the problem of cell retraction of the thermoplastic elastomer is fundamentally solved.

The invention relates to a phenolic foam insulation material improved by glass fiber powder and sericite. The insulation material is characterized by being mainly prepared from the following raw materials: 100 parts of phenolic resin, 2-10 parts of a phenolic resin fluidity improver, 0.5-5 parts of foam stabilizer, 1-10 parts of toughening / reinforcing agents, 6-15 parts of a foaming agent and 6-55 parts of a reactive acid curing agent. The insulation material disclosed by the invention, which adopts polyoxyethylene grafted or blocked water-based methyl silicone oil as the foam stabilizer, is delicate and uniform in foam cells, low in heat conductivity coefficient and good in insulation performance; and the insulation material, by taking the glass fiber powder and the sericite as the toughening / reinforcing agents, can be used for reducing the cost, improving the flame retardation of foam and reducing the smoke density.

The invention discloses an in-vitro foam cell formation model and application thereof in asymptomatic carotid atherosclerosis study. A construction method of the foam cell formation model provided bythe invention comprises the following steps: sequentially culturing, from bottom to top, smooth muscle cells, endothelial cells and mononuclear cells in a cell culture device capable of performing mechanical stretching so as to obtain a multi-cell co-culture system; treating the multi-cell co-culture system by utilizing a low density lipoprotein, applying a tension effect to induce formation of foam cells by virtue of the cell culture device capable of performing mechanical stretching, thus obtaining the foam cell formation model during early occurrence of asymptomatic carotid atherosclerosis.According to the method disclosed by the invention, consumption of an animal model can be reduced, expenditure is saved, an economic and high-efficiency in-vitro screening model is provided for carotid atherosclerosis resistant new drug screening, and the in-vitro foam cell formation model has the advantages of being simple in preparation method, convenient in experimental operation, low in timeconsumption and stable in performance.

The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and / or ZB-1 activity, expression, and / or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and / or preventing vascular disorders / diseases and inflammatory disorders / diseases.

A toner supplying roller which is used in a developing apparatus and has the following characteristics: (1) an average diameter of a foam cell opening portion on a surface of a foam elastic member is 100 to 800 μm, (2) an unopened cell closed by a skin layer of a film thickness of 50 μm or less is present in the surface of the foam elastic member, and (3) assuming that a surface area of the foam elastic member is A, a total area of the foam cell opening portions is B, and a surface area of the unopened cell is C, the following relationship is satisfied:BA+0.2≦B+CA≦0.95.

The invention discloses a polyurethane foam material and a preparation method thereof, and the application of the polyurethane foam material in wound dressing, wherein the polyurethane foam material is particularly suitable for being used as a wound dressing, can be produced in a safe, simple and convenient mode and is high in biological safety. The preparation method of the polyurethane foam material comprises the following steps: 1) mechanically foaming waterborne polyurethane dispersion slurry to form foam slurry; 2) adding a thickener aqueous solution, preferably a sodium alginate aqueoussolution, into the foam slurry, and uniformly stirring to obtain viscous foam slurry; 3) coating a base material with the slurry to obtain a complex; 4) applying a calcium chloride aqueous solution tothe surface, coated with the slurry, of the complex; and 5) drying the composite material obtained in the step (4) to remove water so as to obtain the foam material with a foam cell structure and a compact surface.